Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3104-3116

  Jiang, Wen ^a,b   Zhang, Yun ^a   Xiao, Lan ^a   Van Cleemput, Jamie ^a   Ji, Shao Ping ^a   Bai, Guang ^c   Zhang, Xia ^a,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DEXANABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2 HYDROXYETHYL) 5,8,11,14 EICOSATETRAENAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIOR MODIFICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DENTATE GYRUS; DEPRESSION; EMBRYO; EMBRYO CULTURE; EMBRYO DEVELOPMENT; HIPPOCAMPUS; MALE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY; X IRRADIATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ARACHIDONIC ACIDS; CANNABINOIDS; CELL PROLIFERATION; CELLS, CULTURED; HIPPOCAMPUS; MALE; NEURONS; POLYUNSATURATED ALKAMIDES; RATS; RATS, INBRED F344; RATS, LONG-EVANS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; STEM CELLS; TETRAHYDROCANNABINOL;

EID: 27644433182     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25509     Document Type: Article

References (63)

1. Iversen, L. 2003. Cannabis and the brain. Brain. 126:1252-1270.
2. Pertwee, R.G. 2001. Cannabinoid receptors and pain. Prog. Neurobiol. 63:569-611.
3. Lemberger, L. 1980. Potential therapeutic usefulness of marijuana. Ann. Rev. Pharmacol. Toxicol. 20:151-172.
4. Robson, P. 2001. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry. 178:107-115.
5. Baker, D., Pryce, G., Giovannoni, G., and Thompson, A.J. 2003. The therapeutic potential of cannabis. Lancet Neurol. 2:291-298.
6. Carlini, E.A. 2004. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 44:461-467.
7. Hall, W., Christie, M., and Currow, D. 2005. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 6:35-42.
8. Cui, S.S., et al. 2001. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J. Neurosci. 21:9867-9876.
9. Budney, A.J., Hughes, J.R., Moore, B.A., and Vandrey, R. 2004. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry. 161:1967-1977.
10. Meyer, J.S., and Quenzer, L.F. 2004. Marijuana and the cannabinoids. In Psychopharmacology: drugs, the brain, and behavior. J.S. Meyer and L.F. Quenzer, editors. Sinauer Associates Inc. Sunderland, Massachusetts, USA. 327-345.
11. Fride, E., and Mechoulam, R. 2003. New advances in the identification and physiological roles of the components of the endogenous cannabinoid system. In Molecular biology of drug addiction. R. Maldonado, editor. Humana Press. Totowa, New Jersey, USA. 173-179.
12. Malberg, J.E. 2004. Implications of adult hippocampal neurogenesis in antidepressant action. J. Psychiatry Neurosci. 29:196-205.
13. Eisch, A.J., and Mandyam, C.D. 2004. Drug dependence and addiction, II: adult neurogenesis and drug abuse. Am. J. Psychiatry. 161:426.
14. Cameron, H.A., and McKay, R.D. 2001. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp. Neurol. 435:406-417.
15. van Praag, H., et al. 2002. Functional neurogenesis in the adult hippocampus. Nature. 415:1030-1034.
16. Jiang, W., Wang, J.C., Zhang, Z., Sheerin, A.H., and Zhang, X. 2004. Response of seizure-induced newborn neurons in the dentate gyrus of adult rats to second episode of seizures. Brain Res. 1006:248-252.
17. Shors, T.J. 2004. Memory traces of trace memories: neurogenesis, synaptogenesis and awareness. Trends Neurosci. 27:250-256.
18. Santarelli, L., et al. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 301:805-809.
19. Dulawa, S.C., Holick, K.A., Gundersen, B., and Hen, R. 2004. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology. 29:1321-1330.
20. Eisch, A.J., Barrot, M., Schad, C.A., Self, D.W., and Nestler, E.J. 2000. Opiates inhibit neurogenesis in the adult rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 97:7579-7584.
21. Nixon, K., and Crews, F.T. 2002. Binge ethanol exposure decreases neurogenesis in adult rat hippocampus. J. Neurochem. 83:1087-1093.
22. Abrous, D.N., et al. 2002. Nicotine self-administration impairs hippocampal plasticity. J. Neurosci. 22:3656-3662.
23. Yamaguchi, M., et al. 2004. Repetitive cocaine administration decreases neurogenesis in adult rat hippocampus. Ann. N. Y. Acad. Sci. 1025:351-362.
24. Jin, K., et al. 2004. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 66:204-208.
25. Rueda, D., Navarro, B., Martinez-Serrano, A., Guzman, M., and Galve-Roperh, I. 2002. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J. Biol. Chem. 277:46645-46650.
26. Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K., and Walker, J.M. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:393-411.
27. Bonhaus, D.W., Chang, L.K., Kwan, J., and Martin, G.R. 1998. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287:884-888.
28. Howlett, A.C., et al. 2004. Cannabinoid physiology and pharmacology: 30 years of progress [review]. Neuropharmacology. 47(Suppl. 1):345-358.
29. Radeff-Huang, J., Seasholtz, T.M., Matteo, R.G., and Brown, J.H. 2004. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 92:949-966.
30. Kempermann, G., Gast, D., Kronenberg, G., Yamaguchi, M., and Gage, F.H. 2003. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development. 130:391-399.
31. Zhang, X., et al. 2002. Relations between brain pathology and temporal lobe epilepsy. J. Neurosci. 22:6052-6061.
32. Kempermann, G., Jessberger, S., Steiner, B., and Kronenberg, G. 2004. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 27:447-452.
33. Watts, G. 2004. High hopes for cannabinoidanalgesia. BMJ. 329:257-258.
34. Martin, B.R., Mechoulam, R., and Razdan, R.K. 1999. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:573-595.
35. Tzavara, E.T., Wade, M., and Nomikos, G.G. 2003. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J. Neurosci. 23:9374-9384.
36. Sulcova, E., Mechoulam, R., and Fride, E. 1998. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59:347-352.
37. Welch, S.P., Dunlow, L.D., Patrick, G.S., and Razdan, R.K. 1995. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1235-1244.
38. O'Sullivan, S.E., Kendall, D.A., and Randall, M.D. 2005. Vascular effects of Delta9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyl-dopamine (NADA) in the rat isolated aorta. Eur. J. Pharmacol. 507:211-221.
39. Lutz, B. 2004. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 68:1691-1698.
40. Biscaia, M., et al. 2003. Chronic treatment with CP55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl). 170:301-308.
41. Lucki, I. 1997. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 8:523-532.
42. Cryan, J.F., Markou, A., and Lucki, I. 2002. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23:238-245.
43. Gordon, J.A., and Hen, R. 2004. The serotonergic system and anxiety. Neuromolecular Med. 5:27-40.
44. Onaivi, E.S., Green, M.R., and Martin, B.R. 1990. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253:1002-1009.
45. Arevalo, C., de Miguel, R., and Hernandez-Tristan, R. 2001. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 70:123-131.
46. Marin, S., et al. 2003. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 74:649-656.
47. Genn, R.F., Tucci, S., Marco, E.M., Viveros, M.P., and File, S.E. 2004. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol. Biochem. Behav. 77:567-573.
48. Hill, M.N., and Gorzalka, B.B. 2004. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 499:291-295.
49. Marco, E.M., et al. 2004. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15:21-27.
50. Shearman, L.P., et al. 2003. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14:573-582.
51. Tzavara, E.T., et al. 2003. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138:544-553.
52. Berrendero, F., and Maldonado, R. 2002. Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-tetrahydrocannabinol. Pychopharmacology (Berl). 163:111-117.
53. Genn, R.E., Tucci, S., Marco, E., Viveros, M.P., and File, S.E. 2003. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety. J. Psychopharmacol. 17:A27.
54. Reynolds, B.A., and Weiss, S. 1996. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 175:1-13.
55. Gritti, A., et al. 1996. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J. Neurosci. 16:1091-1100.
56. Persson, A.I., Thorlin, T., Bull, C., and Eriksson, P.S. 2003. Opioid-induced proliferation through the MAPK pathway in cultures of adult hippocampal progenitors. Mol. Cell. Neurosci. 23:360-372.
57. Harada, J., Foley, M., Moskowitz, M.A., and Waeber, C. 2004. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 88:1026-1039.
58. Kanemura, Y., et al. 2002. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. J. Neurosci. Res. 69:869-879.
59. Malberg, J.E., Eisch, A.J., Nestler, E.J., and Duman, R.S. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20:9104-9110.
60. Nixon, K., and Crews, F.T. 2004. Temporally specific burst in cell proliferation increases hippocampal neurogenesis in protracted abstinence from alcohol. J. Neurosci. 24:9714-9722.
61. Crews, F.T., Nixon, K., and Wilkie, M.E. 2004. Exercise reverses ethanol inhibition of neural stem cell proliferation. Alcohol. 33:63-71.
62. West, M.J. 1993. New stereological methods for counting neurons. Neurobiol. Aging. 14:275-285.
63. Bodnoff, S.R., Suranyi-Cadotte, B., Aitken, D.H., Quirion, R., and Meaney, M.J. 1988. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl). 95:298-302.